RSS Feed

Latest news

Combined LABA/steroid inhaler added to Easyhaler range

Combined LABA/steroid inhaler added to Easyhaler range

Fobumix Easyhaler 320/9 (budesonide/formoterol) is...

Tofacitinib approved by NICE for severe rheumatoid arthritis

Tofacitinib approved by NICE for severe rheumatoid arthritis

The JAK inhibitor tofacitinib (Xeljanz) has been endorsed...

New salmeterol/fluticasone MDI extends choice in asthma prescribing

New salmeterol/fluticasone MDI extends choice in asthma prescribing

Aloflute (salmeterol/fluticasone) metered dose inhaler...

NICE approves reslizumab for severe eosinophilic asthma

NICE approves reslizumab for severe eosinophilic asthma

NICE has approved the use of reslizumab (Cinqaero)...

Hepatitis B vaccination added to routine schedule

Hepatitis B vaccination added to routine schedule

The hexavalent DTaP/IPV/HiB/HBV vaccine Infanrix hexa...


New and deleted products

Promo Image

New Products

Products added to MIMS

Promo Image

Deleted Products

Products removed from MIMS


Most popular

Antidepressants, a Guide to Switching and Withdrawing

Instructions for changing or stopping antidepressants.

H.pylori: Eradication Regimens (NICE)

Summary of NICE guidance on Helicobacter treatment.

Hormone Replacement Therapy (HRT)

Hormone doses and costs of HRT preparations.

Topical Steroids, Comparison of Potencies and Formulations

Strengths and formulations of topical steroids.

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.


Featured MIMS resources

Promo Image

Routine childhood immunisation schedule

Quick-reference summary of the UK childhood vaccination programme.

Promo Image

Menopause: diagnosis and management

At-a-glance summary of the new NICE guidance on menopause.


Manufacturers

Manufacturers

Contact details and drug listings for manufacturers in MIMS


New products coming soon to MIMS

Check back soon to find MIMS listings for the following new drugs:

Brinavess (vernakalant)

Fertavid (follitropin beta)

Kyleena (levonorgestrel)

Panzyga (human normal immunoglobulin)

Suliqua (insulin glargine/lixisenatide)

Vemlidy (tenofovir alafenamide fumarate)


Partner CPD from MIMS Learning

knowledge 0.5 Credits

Initiated, funded and reviewed by Reckitt Benckiser. Date of Preparation: February 2017; UK/E45-NHS/0916/0013j

WEBCAST 1 Credit

Lessons from the Ealing GP Federation Funding for this educational programme has been provided by Bayer, Boehringer Ingelheim and Daiichi Sankyo. None of the companies have had any influence or input into its content.

Webcast 0.5 Credits

This learning module has been initiated, funded and reviewed by Edwards Lifesciences.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

This site is intended for healthcare professionals.